Anti-Apolipoprotein E antibody [EPR19392],Abcam,AB183597
Anti-Apolipoprotein E antibody [EPR19392] (ab183597) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IHC-P, IP, WB in human, mouse, rat samples. Anti-Apolipoprotein E antibody [EPR19392] (ab183597) has been cited over 29 times in peer reviewed journals and is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-Apolipoprotein E antibody [EPR19392] (ab183597) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-Apolipoprotein E antibody [EPR19392] (ab183597) has been confirmed by testing in knockout samples. Anti-Apolipoprotein E antibody [EPR19392] (ab183597) specifically detects Apolipoprotein E (UniProt ID: P08226; Molecular weight: 34kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Conjugation-ready, carrier free format available for antibody clone EPR19392 - ab271944 . Antibody clone EPR19392 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 647, Alexa Fluor® 555, Alexa Fluor® 488, PE, APC, HRP, Alkaline Phosphatase, Alexa Fluor® 594 ( ab300743 , ab302567 , ab302580 , ab303050 , ab303051 , ab303052 , ab308649 , ab310350 ). APOE (Apolipoprotein E) is a protein that mediates lipid transport and is crucial for maintaining lipid homeostasis in the brain. The APOE gene has three primary alleles: E2, E3, and E4. The APOE4 allele significantly increases the risk of Alzheimer's disease by promoting amyloid-beta aggregation and neuroinflammation. In contrast, the APOE2 allele provides a protective effect against Alzheimer's, demonstrating the complex influence of APOE on brain health and disease. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Mouse, Rat, Human
Application
Flow Cyt (Intra), IHC-P, IP, ICC/IF, WB
Platform ID
BAB839054056

Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed : 14754908, PubMed : 1911868, PubMed : 6860692). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed : 14754908, PubMed : 1911868, PubMed : 1917954, PubMed : 23620513, PubMed : 2762297, PubMed : 6860692, PubMed : 9395455). Apolipoproteins are amphipathic molecules that interact both with lipids of the lipoprotein particle core and the aqueous environment of the plasma (PubMed : 2762297, PubMed : 6860692, PubMed : 9395455). As such, APOE associates with chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but shows a preferential binding to high-density lipoproteins (HDL) (PubMed : 1911868, PubMed : 6860692). It also binds a wide range of cellular receptors including the LDL receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR that mediate the cellular uptake of the APOE-containing lipoprotein particles (PubMed : 12950167, PubMed : 1530612, PubMed : 1917954, PubMed : 20030366, PubMed : 20303980, PubMed : 2063194, PubMed : 2762297, PubMed : 7635945, PubMed : 7768901, PubMed : 8756331, PubMed : 8939961). Finally, APOE also has a heparin-binding activity and binds heparan-sulfate proteoglycans on the surface of cells, a property that supports the capture and the receptor-mediated uptake of APOE-containing lipoproteins by cells (PubMed : 23676495, PubMed : 7635945, PubMed : 9395455, PubMed : 9488694). A main function of APOE is to mediate lipoprotein clearance through the uptake of chylomicrons, VLDLs, and HDLs by hepatocytes (PubMed : 1911868, PubMed : 1917954, PubMed : 23676495, PubMed : 29516132, PubMed : 9395455). APOE is also involved in the biosynthesis by the liver of VLDLs as well as their uptake by peripheral tissues ensuring the delivery of triglycerides and energy storage in muscle, heart and adipose tissues (PubMed : 2762297, PubMed : 29516132). By participating in the lipoprotein-mediated distribution of lipids among tissues, APOE plays a critical role in plasma and tissues lipid homeostasis (PubMed : 1917954, PubMed : 2762297, PubMed : 29516132). APOE is also involved in two steps of reverse cholesterol transport, the HDLs-mediated transport of cholesterol from peripheral tissues to the liver, and thereby plays an important role in cholesterol homeostasis (PubMed : 14754908, PubMed : 23620513, PubMed : 9395455). First, it is functionally associated with ABCA1 in the biogenesis of HDLs in tissues (PubMed : 14754908, PubMed : 23620513). Second, it is enriched in circulating HDLs and mediates their uptake by hepatocytes (PubMed : 9395455). APOE also plays an important role in lipid transport in the central nervous system, regulating neuron survival and sprouting (PubMed : 25173806, PubMed : 8939961). APOE is also involved in innate and adaptive immune responses, controlling for instance the survival of myeloid-derived suppressor cells (By similarity). Binds to the immune cell receptor LILRB4 (PubMed : 30333625). APOE may also play a role in transcription regulation through a receptor-dependent and cholesterol-independent mechanism, that activates MAP3K12 and a non-canonical MAPK signal transduction pathway that results in enhanced AP-1-mediated transcription of APP (PubMed : 28111074).. (Microbial infection) Through its interaction with HCV envelope glycoprotein E2, participates in the attachment of HCV to HSPGs and other receptors (LDLr, VLDLr, and SR-B1) on the cell surface and to the assembly, maturation and infectivity of HCV viral particles (PubMed : 25122793, PubMed : 29695434). This interaction is probably promoted via the up-regulation of cellular autophagy by the virus (PubMed : 29695434). See full target information APOE
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.
